Actively Recruiting
Clenbuterol to Target DUX4 in FSHD
Led by Jeffrey Statland · Updated on 2026-02-25
30
Participants Needed
3
Research Sites
157 weeks
Total Duration
On this page
Sponsors
J
Jeffrey Statland
Lead Sponsor
U
University of Washington
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
CONDITIONS
Official Title
Clenbuterol to Target DUX4 in FSHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Genetically confirmed diagnosis of FSHD type 1 or 2, or clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation
- Between 18 and 75 years of age
- Clinical severity score between 0 and 10
- Able to walk 30 feet without support of another person
- Showing anti-gravity strength on at least one tibialis anterior muscle or having an MRI eligible muscle in the leg for needle biopsy
- Willing and able to provide informed consent
- Agree to follow the contraceptive requirement for the duration of the study
You will not qualify if you...
- Pregnant or planning to become pregnant during the conduct of the study
- Have a poorly controlled medical condition
- Involved in a study of an experimental agent within 3 months of enrollment
- Taking beta-blockers, anabolic agents, or potassium wasting diuretics
- Taking or planning to take a GLP-1 Agonist during the trial
- Have any condition or contraindication which would interfere with testing or preclude use of beta-agonist
- Taking blood thinners or medications that contraindicate needle muscle biopsy
- Have contraindication to lactose such as galactosmia, lactase deficiency, or glucose-galactose malabsorption
- Taking any medications or therapies contraindicated with Clenbuterol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Actively Recruiting
2
University of Rochester Medical Center
Rochester, New York, United States, 14642
Actively Recruiting
3
University of Washington
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
R
Rebecca Clay
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here